Evaluating Guardant Health: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Guardant Health (NASDAQ:GH) has received mixed ratings from 5 analysts over the past three months, with a range of bullish to bearish perspectives. The average 12-month price target has decreased from $39.00 to $32.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Guardant Health has shown significant revenue growth but faces challenges in profitability, return on equity, return on assets, and debt management.
May 24, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guardant Health has received mixed ratings from analysts, with a decrease in the average 12-month price target from $39.00 to $32.00. The company has shown strong revenue growth but faces challenges in profitability, return on equity, return on assets, and debt management.
The mixed analyst ratings and lowered price targets indicate uncertainty about Guardant Health's short-term performance. While the company has shown strong revenue growth, significant challenges in profitability, return on equity, return on assets, and debt management may offset positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100